{"id":"W4415756350","doi":"10.1016/j.jhepr.2025.101658","title":"Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib – A phase II trial (PEMRAD)","year":2025,"lang":"en","type":"article","venue":"JHEP Reports","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Toronto General Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"Merck Canada; Princess Margaret Cancer Foundation; Merck","keywords":"Pembrolizumab; Sorafenib; Hepatocellular carcinoma; Clinical trial; Radiation therapy; Hepatocellular cancer; Stereotactic radiotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001018951,0.0006004182,0.001182957,0.0002413375,0.0001942709,0.0005638242,0.0003367776,0.0004692258,0.00277713],"category_scores_gemma":[0.0004263174,0.0001893414,0.0006684128,0.000212466,0.0003074416,0.0003084739,0.0002061271,0.0012129,0.0004903271],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004033956,"about_ca_system_score_gemma":0.0005956455,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003768555,"about_ca_topic_score_gemma":0.001006673,"domain_scores_codex":[0.9997713,0.0001145376,0.00001426087,0.00003347357,0.00002179593,0.00004454331],"domain_scores_gemma":[0.9997774,0.00003775814,0.00005511504,0.00001672354,0.00001703401,0.00009600451],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7149531,0.01487358,0.005954981,0.00185644,0.002350749,0.0003515324,0.0001278183,0.002840837,0.02346083,0.0005388049,0.005450382,0.2272409],"study_design_scores_gemma":[0.6829626,0.2821129,0.01782863,0.000144946,0.0009383819,0.0006440264,0.0000561676,0.001981443,0.004803958,0.0003104736,0.008190975,0.00002563568],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9823516,0.01152434,0.0005203353,0.0005733684,0.0001468475,0.001410513,0.000673739,0.0000921729,0.002707049],"genre_scores_gemma":[0.987691,0.004129388,0.001332294,0.0005620562,0.0002300953,0.001621316,0.00148135,0.00001401092,0.002938478],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00277713,"threshold_uncertainty_score":0.009290397,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02267633328266469,"score_gpt":0.2841846377125806,"score_spread":0.2615083044299159,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}